Related Experiment Videos
[Pharmacosurveillance III: international experience]
Leticia Rodríguez Betancourt1, José Luis García Vigil, Carmen Giral Barnés
1Centro de Información de Medicamentos, Universidad Autonoma del Estado de Morelos (IMSS-UAEM), USA.
Revista Medica Del Instituto Mexicano Del Seguro Social
|August 11, 2005
Summary
This study examines global adverse drug reaction reports, identifying leading countries and therapeutic classes. It analyzes reporting trends adjusted for population size, offering insights into drug safety worldwide.
Area of Science:
- Pharmacovigilance and Drug Safety
- International Health and Epidemiology
- Clinical Pharmacology
Context:
- Adverse drug reactions (ADRs) represent a significant global health concern.
- Understanding international ADR reporting patterns is crucial for effective drug safety surveillance.
- Previous research has established the importance of pharmacovigilance but lacks comprehensive international comparative analysis.
Purpose:
- To analyze and compare international experiences with adverse drug reactions (ADRs).
- To identify countries with the highest cumulative ADR report numbers and assess population-adjusted reporting rates.
- To detail the frequency of ADRs across twenty therapeutic drug classes and their associated clinical manifestations.
Summary:
- This article presents an analysis of global ADR data, highlighting leading countries based on cumulative and population-adjusted report numbers.
- It ranks twenty therapeutic drug classes by ADR report frequency, providing explanations for observed patterns.
- The study also consolidates data on the cumulative reports for specific clinical manifestations of ADRs.
Impact:
- Provides a global perspective on drug safety and pharmacovigilance activities.
- Informs regulatory bodies and healthcare professionals about high-risk therapeutic areas and geographical trends in ADRs.
- Facilitates targeted interventions and resource allocation for improving international drug safety monitoring.